1 	|BT| (S (NP (NN Hes1) (NN induction)) (VP (VBD mediated) (SBAR (S (NP (NN beta-catenin)) (VP (VBD resulted) (NP (NN induction) (NN Notch) (NN ligand/receptor) (JJ Notch-independent) (NN control) (NN Hes1) (NN promoter) (NN beta-catenin))))))) |ET| |BS|23:D12.776.091.249 170:D27.720.470.480|ES| 19:1 60:1 83:1 256:1 258:1 289:1 437:1 594:1 736:1 4871:1 4872:1

1 	|BT| (S (NP (JJ Hexavalent) (NN chromium)) (VP (VBZ induces) (NP (JJ malignant) (NN transformation) (JJ human) (NN lung) (JJ bronchial) (JJ epithelial) (NN cell)) (PP (IN via) (NP (JJ ROS-dependent) (NN activation) (NN miR-21-PDCD4) (NN signaling))))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400 69:G02.111.087.800 75:A11.436 231:C04.557.465.625.600.380.590 1364:C08.127.509|ES| 19:1 36:1 94:1 127:1 195:1 214:1 225:1 328:1 596:1 802:1 1384:1 4873:1 4874:1 4875:1 4876:1 4877:1

1 	|BT| (S (NP (NN Histone) (NN deacetylase) (NN inhibitor)) (VP (VBP suppress) (SBAR (S (NP (NN thymidylate) (NN synthase) (NN gene) (NN expression)) (VP (VBP synergize) (NP (NNS fluoropyrimidines) (NP (NN colon) (NN cancer) (NN cell)))))))) |ET| |BS|41:A11 153:D27.505.519.389.360 155:G05.355.310 713:D08.811.913.555.500.862|ES| 9:1 18:1 19:1 66:1 94:1 113:1 115:1 380:1 504:1 2441:1 2578:1 3528:1 4878:1 4879:1

1 	|BT| (S (NP (NN HO-3867)) (VP (VBD induced) (NP (NN G) (S (-LRB- -LRB-) (NP (NP (CD 2) (-RRB- -RRB-) (: -)) (NP (NP (NN M) (NN cell) (NN cycle) (NN arrest) (NN A2780) (NN cell) (NN modulating) (NN cell) (NN cycle) (JJ regulatory) (NN molecule) (NN p53)) (, ,) (NP (NN p21)) (, ,) (NP (NN p27)) (, ,) (NP (JJ cyclin-dependent) (NN kinase) (CD 2)) (, ,) (NP (NN cyclin)) (, ,))) (VP (VBD promoted) (NP (NN apoptosis) (NN caspase-8) (NN caspase-3) (NN activation))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 39:G04.299.139.160 41:A11 353:G04.299.134 768:D12.776.660.740 773:G04.299.134.109 906:D08.811.277.656.262.500.126.350.300 1034:D08.811.277.656.262.500.126.550.800 1280:D12.644.360.262 1365:D08.811.913.696.620.682.700.646.500.750|ES| 2:1 10:1 12:1 14:1 19:1 89:1 94:1 148:1 180:1 225:1 412:1 470:1 601:1 602:1 743:1 1124:1 1135:1 1817:1 1912:1 2435:1 3016:1 3612:1 4546:1 4807:1 4880:1 4881:1 4882:1

1 	|BT| (S (ADVP (RB However)) (, ,) (NP (NP (NNS pretreatments) (NP (NP (JJ selective) (JJ mitogen-activated) (NN protein) (NN kinase)) (PRN (-LRB- -LRB-) (NP (NN MAPK)) (-RRB- -RRB-))) (NN inhibitor)) (, ,) (NP (NP (NP (NP (NN SB203580)) (PRN (-LRB- -LRB-) (NP (NN p38) (NN inhibitor)) (-RRB- -RRB-))) (NN PD0325901)) (PRN (-LRB- -LRB-) (NP (NN ERK1/2) (NN inhibitor)) (-RRB- -RRB-))) (, ,)) (ADVP (RB significantly)) (VP (VBD suppressed) (NP (NN activation) (NN EGCG) (NN BTG2) (NN expression)))) |ET| |BS|116:D08.811.913.696.620.682.700.567.249.750 478:D08.811.913.696.620.682.700.567|ES| 2:1 4:1 10:1 14:1 19:1 115:1 124:1 225:1 307:1 380:1 433:1 470:1 809:1 1666:1 1749:1 2525:1 3295:1 4594:1 4883:1 4884:1 4885:1 4886:1

1 	|BT| (S (ADVP (RB Importantly)) (, ,) (NP (NN cotreatment) (JJ low) (NNS dos) (NP (NP (NNS oligoamines) (NN DNA) (NN methyltransferase) (NN inhibitor)) (ADVP (RB highly)))) (VP (VBZ induces) (SBAR (S (NP (NN reexpression)) (ADVP (RB aberrantly)) (VP (VBD silenced) (SBAR (S (NP (NN SFRP2) (NN gene)) (VP (VBP result) (NP (NP (JJ significant) (NN inhibition) (NN growth)) (VBN established) (NN tumor) (JJ human) (NN colon) (NN tumor) (NN model)) (FW vivo))))))))) |ET| |BS|6:G05.360.340.024.340 8:C04 43:F01.145.544 45:G07.700.320.249 51:C04.588.274.476.411.307.180 55:B01.050.150.900.649.801.400.112.400.400 618:E02.186 746:D08.811.150.240|ES| 2:1 7:1 9:1 19:1 36:1 72:1 101:1 102:1 103:1 113:1 135:1 214:1 378:1 380:1 531:1 626:1 666:1 2651:1 2652:1 2653:1 2654:1 2655:1 2656:1 2657:1 2658:1 2659:1 2660:1

1 	|BT| (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NN reporter) (NN assay)) (VP (VBD indicated) (SBAR (S (NP (NN FXRE) (NN promoter) (NN activity)) (ADVP (RB significantly)) (VP (VBD increased) (NP (NP (NN treatment) (NN ACR)) (CC plus) (NP (NN GW4064)))))))) |ET| |BS|52:E02 106:E05.091|ES| 2:1 19:1 47:1 83:1 124:1 244:1 288:1 310:1 399:1 468:1 546:1 1541:1 4503:1 4504:1 4887:1 4888:1

1 	|BT| (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NN PIM) (NN kinase)) (VP (VBP activate) (S (NP (NN MYC) (NN signaling) (NN mRNA) (NN translation) (NN prostate) (NN cancer)) (VP (VBP cooperate) (S (NP (NN MYC)) (VP (VB accelerate) (NP (NN tumorigenesis)))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 32:C04.697.098.500 33:C04.697.098 69:G02.111.087.800 145:G02.111.087.675.871|ES| 2:1 18:1 19:1 77:1 78:1 195:1 244:1 325:1 468:1 469:1 470:1 471:1 472:1 473:1 474:1 475:1

1 	|BT| (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NN treatment) (JJ nude) (NN mouse) (NN isochaihulactone)) (NP (VBD increased) (FW vivo) (NN NAG-1) (NN expression)) (VP (VBD examined) (NP (NN immunohistochemistry) (NN tumor) (NN biopsy)))) |ET| |BS|8:C04 52:E02 88:B01.050.150.900.649.865.635.505.500.550.500 143:E01.370.225.500.607.512 559:E01.370.225.500.384.100|ES| 2:1 7:1 19:1 47:1 52:1 115:1 244:1 266:1 324:1 378:1 468:1 546:1 833:1 1662:1 1984:1 4889:1

1 	|BT| (S (PP (IN In) (NP (NN addition))) (, ,) (NP (JJ ursolic) (NN acid)) (VP (VBD suppressed) (NP (ADJP (NP (NP (NN EGF) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN EGFR)) (-RRB- -RRB-))) (VBD induced)) (NN p53) (NN p21) (NN expression)))) |ET| |BS|2:G05.360.340.024.340.375.249.385 64:D08.811.913.696.620.682.725.400.009.300|ES| 2:1 10:1 12:1 14:1 19:1 115:1 186:1 187:1 244:1 307:1 412:1 468:1 1135:1 1275:1 4890:1 4891:1

1 	|BT| (S (PP (IN In) (NP (JJ AR-positive) (NN bladder) (NN cancer) (NN cell) (NN line))) (, ,) (NP (NN dihydrotestosterone) (NN treatment)) (VP (VP (VBD increased) (NP (NP (NP (NN ELK1)) (NN expression)) (PRN (-LRB- -LRB-) (NP (NP (NN mRNA)) (, ,) (NP (NN protein))) (-RRB- -RRB-))) (S (VP (JJ nuclear) (NP (NP (NN translocation)) (, ,) (NP (NN ELK1) (JJ transcriptional) (NN activity)) (, ,) (NP (NN c-fos)) (NP (NN expression)) (, ,))))) (VP (VBD restored) (NP (JJ anti-androgen) (NN hydroxyflutamide))))) |ET| |BS|7:D12.776 52:E02 94:A11.251.210 111:D13.444.735.544 165:G05.360.340.024.340.375.500.791.330 209:G02.111.087.847 463:C23.550.210.870 1287:D04.808.054.040.248 1288:D06.347.065 1366:D12.776.260.108.765|ES| 2:1 4:1 10:1 14:1 18:1 19:1 47:1 94:1 115:1 244:1 264:1 325:1 399:1 546:1 558:1 559:1 562:1 564:1 1256:1 1618:1 4578:1 4892:1 4893:1 4894:1 4895:1

1 	|BT| (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (NN study)) (VP (VBP show) (SBAR (S (NP (NN TS) (NN gene) (NN expression) (NN pretreatment) (NN biopsy)) (VP (VBZ predicts) (NP (NN response) (JJ local) (JJ rectal) (NN cancer) (JJ neo-adjuvant) (JJ 5-FU-based) (NN chemoradiotherapy) (JJ high) (NN percentage))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 154:Z01.058.266.887 155:G05.355.310 333:D01.045 559:E01.370.225.500.384.100 560:D03.383.742.698.875.404 561:E02.186.079.500|ES| 2:1 9:1 18:1 19:1 115:1 131:1 178:1 244:1 429:1 494:1 509:1 1284:1 1751:1 1983:1 1984:1 1985:1 1986:1 1987:1 1988:1 1989:1 1990:1

1 	|BT| (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (NN troglitazone)) (VP (VBD attenuated) (NP (NN Skp2) (NN expression)) (, ,) (S (VP (ADVP (RB thereby)) (NP (VBG promoting) (NP (NN p27) (-LRB- -LRB-) (NN Kip1) (-RRB- -RRB-) (NN accumulation) (JJ human) (NN hepatoma) (NN cell))))))) |ET| |BS|41:A11 55:B01.050.150.900.649.801.400.112.400.400 104:C04.557.470.200.025.255 338:D12.644.360.225.600 507:D12.776.157.743 515:C04.588.274.623|ES| 2:1 10:1 14:1 19:1 36:1 94:1 115:1 244:1 808:1 881:1 1124:1 1125:1 1284:1 1785:1 2120:1 3896:1 4508:1 4896:1

1 	|BT| (S (PP (IN In) (NP (NN conclusion))) (, ,) (VP (VBD found) (NP (NP (NN U0126) (JJ atypical) (NN PXR) (NN ligand)) (PP (IN via) (NP (NP (NP (NP (JJ direct)) (PRN (-LRB- -LRB-) (NP (NN binding) (NN activation) (NN PXR)) (-RRB- -RRB-))) (ADJP (ADJP (JJ indirect)) (PRN (-LRB- -LRB-) (NP (NN SHP) (NN dowregulation)) (-RRB- -RRB-)))) (NN mechanism)))) (PP (ADVP (RB selectively)) (VBZ restores) (NP (NN CYP3A) (NN gene) (NN HepG2) (NN cell))))) |ET| |BS|6:G05.360.340.024.340 170:D27.720.470.480 1015:A11.251.860.180.432|ES| 2:1 9:1 10:1 14:1 19:1 37:1 94:1 162:1 225:1 244:1 596:1 1284:1 1487:1 1835:1 1891:1 2382:1 3481:1 3523:1 4897:1 4898:1 4899:1 4900:1 4901:1 4902:1 4903:1

1 	|BT| (FRAG (PP (IN In) (NP (NN LNCaP) (NN cell))) (, ,) (NP (NP (JJ caspase-mediated) (NN apoptosis) (NN induction) (NN PGG)) (SBAR (S (NP (VBN associated) (JJ mediated) (JJ major) (NN part) (NN activation) (NN p53)) (VP (VBD established) (NP (JJ small) (VBG interfering) (NN RNA) (NN knockdown) (JJ dominant-negative) (JJ mutant) (NN approach))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 38:Z01.058.290.120.180 39:G04.299.139.160 40:Z01.542.248.700 41:A11 117:D13.150.650.700 133:D01.248.497.158.685.750.744.600 1367:D08.811.277.656.262.500.126|ES| 2:1 12:1 19:1 89:1 94:1 169:1 225:1 244:1 413:1 437:1 451:1 462:1 464:1 515:1 736:1 750:1 811:1 911:1 2115:1 2660:1 3019:1 4904:1 4905:1

1 	|BT| (S (PP (IN In) (NP (NP (NP (NN mouse) (JJ ovarian) (JJ endometrioid) (NN adenocarcinoma)) (PRN (-LRB- -LRB-) (NP (NNS OEAs)) (-RRB- -RRB-))) (VP (VBG arising) (NP (NN Apc))))) (: -) (NP (NP (NN Pten-inactivation)) (, ,) (NP (NN Ctnnb1) (JJ hemizygous) (NN dose))) (VP (VBD affected) (NP (NP (NN beta-catenin) (NN level) (NN beta-catenin/TCF) (NN target) (NN gene)) (, ,) (NP (NN Myc) (NN induction))) (VP (VBD retained) (SBAR (S (NP (NNS OEAs)) (VP (VBD arose) (NP (NP (NN fashion) (JJ akin)) (VBN seen) (JJ intact) (NN Ctnnb1) (NN gene) (NN dose)))))))) |ET| |BS|3:C04.557.470.035.215.100 6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 23:D12.776.091.249 213:F02.830.816.964 433:F01.470.047 1368:C04.557.470.200.025.240 1369:A05.360.319.114.630|ES| 2:1 9:1 10:1 14:1 19:1 52:1 60:1 160:1 244:1 249:1 255:1 724:1 736:1 1577:1 1763:1 1786:1 2301:1 4032:1 4422:1 4722:1 4754:1 4906:1 4907:1 4908:1 4909:1 4910:1 4911:1 4912:1 4913:1 4914:1

1 	|BT| (S (PP (IN In) (NP (NN summary))) (, ,) (NP (NN SAHA)) (VP (VP (VBD inhibited) (S (NP (NN growth) (JJ human) (JJ pancreatic) (NN cancer) (NN cell)) (VP (VBG inducing) (NP (NN apoptosis))))) (, ,) (NP (NP (NN differentiation) (NN cell) (NN cycle) (NN arrest)) (, ,) (ADVP (RB well)) (NP (NN increase) (NN expression) (JJ several) (NN tumor) (NN suppressor) (NN gene))))) |ET| |BS|39:G04.299.139.160 41:A11 45:G07.700.320.249 55:B01.050.150.900.649.801.400.112.400.400 74:G04.299.151 122:C14.280.383 206:G05.360.340.024.340.375.249 773:G04.299.134.109|ES| 2:1 7:1 9:1 18:1 19:1 36:1 40:1 89:1 94:1 102:1 115:1 215:1 244:1 262:1 365:1 467:1 490:1 601:1 602:1 700:1 787:1 1864:1 4915:1

1 	|BT| (S (PP (IN In) (NP (NN summary))) (, ,) (NP (JJ small) (NN molecule) (NN inhibitor) (NN imatinib)) (VP (VP (VBZ attenuates) (NP (JJ stromal) (NN cell) (NN proliferation) (JJ PDGF-C-induced) (NN HCC))) (, ,) (VP (VBZ coincides) (NP (NP (VBN decreased) (NN expression) (NN CD34) (NN PDGFRalpha)) (, ,) (NP (VBN activated) (NN Akt)))))) |ET| |BS|104:C04.557.470.200.025.255 183:G04.299.233.750 378:D08.811.913.696.620.682.700.755 1370:D08.811.913.696.620.682.725.400.900.500|ES| 2:1 19:1 94:1 115:1 163:1 180:1 202:1 244:1 299:1 380:1 441:1 490:1 750:1 1289:1 2423:1 4916:1 4917:1 4918:1 4919:1 4920:1 4921:1

1 	|BT| (S (PP (IN In) (NP (NN H1373) (NN xenograft) (NN model))) (, ,) (NP (NN treatment) (NN JQ1)) (ADVP (RB significantly)) (VP (VBD reduced) (SBAR (S (NP (NN tumor) (NN growth)) (VP (VBD downregulated) (NP (NN expression) (NN c-Myc))))))) |ET| |BS|8:C04 45:G07.700.320.249 52:E02 92:E04.936.764 93:A01.941.875|ES| 2:1 7:1 19:1 72:1 102:1 115:1 124:1 244:1 265:1 426:1 452:1 546:1 824:1 4922:1 4923:1

1 	|BT| (S (PP (IN In) (NP (JJ present) (NN study))) (, ,) (NP (NP (NN report) (NN vitro) (NN treatment) (JJ primary) (NN hepatoma)) (, ,) (NP (NP (NN HepG2)) (PRN (-LRB- -LRB-) (NP (JJ wild-type) (NN p53)) (-RRB- -RRB-))) (, ,) (NP (NP (NN PLC/PRF/5)) (PRN (-LRB- -LRB-) (NP (NN p53-mutant)) (-RRB- -RRB-))) (, ,) (NP (NP (NN Hep3B)) (PRN (-LRB- -LRB-) (ADJP (JJ p53-deleted)) (-RRB- -RRB-))) (NP (NP (NN cell) (NN 2-chloroethyl-3-sarcosinamide-1-nitrosourea)) (PRN (-LRB- -LRB-) (NP (NN SarCNU)) (-RRB- -RRB-)))) (VP (VBD resulted) (NP (NP (NN upregulation) (NN p53) (, ,) (NN p21) (-LRB- -LRB-) (NN Cip1/Waf1) (-RRB- -RRB-)) (, ,) (NP (NP (VBN phosphorylated) (NN cdc-2) (NN Tyr15) (JJ wild-type) (NN p53) (NN cell) (NN phosphorylation) (NN cdc-2) (NN Tyr15)) (NP (JJ p53-mutant) (NP (JJ p53-deleted) (NN hepatoma) (NN cell))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 41:A11 52:E02 104:C04.557.470.200.025.255 249:G05.355.315.800 339:G02.111.087.880 515:C04.588.274.623 972:G02.111.087.677 1371:I01.409.418.750.600.650.225|ES| 2:1 8:1 10:1 12:1 14:1 19:1 94:1 131:1 216:1 244:1 344:1 417:1 546:1 594:1 1126:1 1135:1 1307:1 3426:1 3481:1 3896:1 4502:1 4924:1 4925:1 4926:1 4927:1 4928:1 4929:1 4930:1 4931:1 4932:1

1 	|BT| (S (PP (IN In) (NP (NN study))) (, ,) (VP (VBP demonstrate) (S (NP (NP (NP (NN histone) (NN deacetylase) (NN inhibitor)) (PRN (-LRB- -LRB-) (NP (NN HDACi)) (-RRB- -RRB-))) (NN vorinostat) (NN LBH589)) (VP (ADVP (RB significantly)) (VBP downregulate) (NP (NN TS) (NN gene) (NN expression) (NN panel) (NN colon) (NN cancer) (NN cell) (NN line)))))) |ET| |BS|94:A11.251.210 153:D27.505.519.389.360 154:Z01.058.266.887 155:G05.355.310|ES| 2:1 9:1 10:1 14:1 18:1 19:1 94:1 113:1 115:1 124:1 131:1 244:1 264:1 380:1 502:1 503:1 504:1 505:1 506:1 507:1 508:1 509:1 510:1

1 	|BT| (NP (NP (PP (IN In) (NP (NP (NN tumor) (NN mouse) (VBN treated) (NN DEN)) (ADVP (RB alone)))) (, ,) (NP (NP (NP (NN prevalence) (NN Ha-ras) (NN mutation)) (NP (ADJP (QP (RB approximately) (CD 30)) (NN %)) (PRN (-LRB- -LRB-) (NP (CD 6/20)) (-RRB- -RRB-)))) (, ,) (NP (NP (NN beta-catenin) (NN mutation)) (PRN (-LRB- -LRB-) (NP (CD 0/13)) (-RRB- -RRB-))) (NP (JJ detectable) (NN tumor) (NN treatment) (NN group))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 8:C04 11:B01.050.150.900.649.865.635.505.500 18:G05.365.590 23:D12.776.091.249 52:E02 60:E05.318.308.985.525.750 216:Z01.107.084.900.425 829:M01.686|ES| 2:1 7:1 10:1 14:1 19:1 34:1 52:1 60:1 179:1 241:1 244:1 369:1 546:1 747:1 1099:1 1520:1 1843:1 1875:1 2300:1 4933:1 4934:1 4935:1

1 	|BT| (S (NP (ADJP (FW In) (FW vivo)) (NN treatment) (NN imatinib)) (ADVP (RB also)) (VP (VBP block) (NP (NN expression) (NN CD34) (NN PDGF-C) (NN Tg) (NN mouse)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 52:E02 122:C14.280.383|ES| 5:1 19:1 52:1 115:1 244:1 378:1 546:1 742:1 4916:1 4920:1 4936:1 4937:1

1 	|BT| (NP (NP (NP (NN Incubation) (NNS pro-oxidants) (JJ arachidonic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN AA)) (-RRB- -RRB-))) (, ,) (NP (NN beta-naphtoflavone)) (, ,) (NP (NN H) (-LRB- -LRB-) (CD 2) (-RRB- -RRB-) (S (NP (NN O) (-LRB- -LRB-) (CD 2) (-RRB- -RRB-)) (VP (VBD enhanced) (NP (NP (NP (NN KLF6)) (PRN (-LRB- -LRB-) (ADJP (JJ Full)) (-RRB- -RRB-))) (NN splice) (NN variant)))))) |ET| |BS|636:D01.339.431 1014:D10.251.355.255.100.100 1356:D01.268.406.500|ES| 2:1 10:1 14:1 19:1 148:1 385:1 517:1 612:1 990:1 1275:1 3553:1 4116:1 4683:1 4684:1 4853:1 4938:1 4939:1 4940:1

1 	|BT| (S (NP (NN Inhibition) (NN FoxM1) (NN expression) (NNS TZDs)) (VP (VBZ provides) (SBAR (S (NP (JJ new) (NN mechanism) (NN TZD)) (VP (VBD mediated) (NP (JJ negative) (NN regulation) (NN cancer) (NN cell) (NN growth))))))) |ET| |BS|41:A11 43:F01.145.544 45:G07.700.320.249 142:I01.880.604|ES| 18:1 19:1 94:1 102:1 115:1 162:1 437:1 438:1 449:1 712:1 815:1 2703:1 3119:1 4791:1 4941:1

1 	|BT| (S (NP (NN Inhibition) (JJ functional) (NN p53) (NN glioblastoma) (NN cell)) (ADVP (RB significantly)) (VP (VBD reduced) (NP (JJ anti-proliferative) (NN effect) (NN celecoxib)))) |ET| |BS|2:G05.360.340.024.340.375.249.385 41:A11 43:F01.145.544 592:C04.557.465.625.600.380.080.335 684:D02.065.884.247|ES| 12:1 19:1 75:1 94:1 124:1 415:1 452:1 2186:1 2703:1 2807:1 3695:1

1 	|BT| (S (NP (NP (NN Inhibition) (JJ isochaihulactone-induced) (NN NAG-1) (NN expression) (NN EGR-1)) (ADJP (JJ small) (S (VP (VBG interfering) (NP (NN RNA)))))) (VP (VBD blocked) (NP (JJ isochaihulactone-induced) (NN apoptosis) (NN A549) (NN cell)) (, ,) (S (VP (VBG suggesting) (NP (NN induction) (NN EGR-1) (NN expression) (NN decrease) (NN survival) (NN A549) (NN cell)))))) |ET| |BS|39:G04.299.139.160 41:A11 43:F01.145.544 108:G04.299.316 117:D13.150.650.700 122:C14.280.383 580:D12.776.260.158.500|ES| 2:1 19:1 89:1 94:1 115:1 274:1 295:1 364:1 515:1 736:1 750:1 1009:1 1662:1 2703:1 2777:1 3019:1 3874:1 4942:1

1 	|BT| (S (NP (NN Inhibition) (NN JNK) (NN chemical) (JJ genetic) (NN method)) (VP (VBD attenuated) (NP (JJ NaBT-induced) (NN PTEN) (NN expression)))) |ET| |BS|43:F01.145.544 1372:E05.393|ES| 19:1 115:1 808:1 864:1 1599:1 1936:1 2124:1 2703:1 4276:1 4943:1

1 	|BT| (FRAG (ADVP (RB Interestingly)) (, ,) (NP (NP (JJ DEN-induced) (NN Pol) (CD III) (NN gene) (NN transcription) (NN H3S10ph) (NN tumor) (NN cell) (NN liver)) (NP (ADJP (RB significantly) (JJR higher)) (NP (JJ non-tumor) (NN cell))))) |ET| |BS|8:C04 41:A11 209:G02.111.087.847 515:C04.588.274.623 614:G05.360.340.024.340.364.875.667 1373:Z01.542.248.679|ES| 2:1 7:1 9:1 19:1 94:1 124:1 170:1 487:1 518:1 836:1 2280:1 2281:1 2735:1 4944:1 4945:1

1 	|BT| (S (NP (JJ Intracellular) (NN beta-catenin) (NN level)) (ADVP (RB slightly)) (VP (VBD reduced) (SBAR (S (NP (JJ NDRG2-transfected) (NN SW620) (NN cell) (NN regulation) (NN beta-catenin) (NN stability) (NN TCF/LEF) (NN activity)) (VP (VBD mediated) (NP (NP (NN modulation) (NN glycogen) (NN synthase) (NN kinase-3beta)) (NN activity) (NN NDRG2) (NN function))))))) |ET| |BS|23:D12.776.091.249 41:A11 142:I01.880.604 924:A11.284.430.214|ES| 19:1 33:1 60:1 66:1 92:1 93:1 94:1 249:1 399:1 437:1 438:1 452:1 1945:1 4946:1 4947:1 4948:1 4949:1 4950:1 4951:1 4952:1

1 	|BT| (NP (NP (NP (NP (JJ Intratumoral) (NN injection) (JJ anti-Wnt-1) (NN antibody)) (NP (VBD suppressed) (FW vivo) (NN tumor) (NN growth) (NN Huh7) (NN xenograft) (NN model))) (, ,) (NP (NP (ADVP (RB also)) (VBN associated) (NN apoptosis)) (VP (VBD reduced) (NP (NP (NN c-Myc)) (, ,) (NP (NN cyclin) (NN D1)) (, ,) (NP (NN survivin) (NN expression))))))) |ET| |BS|8:C04 39:G04.299.139.160 45:G07.700.320.249 92:E04.936.764 93:A01.941.875 215:D12.644.360.262.150.100 1374:E02.095.465.425.400.330|ES| 2:1 5:1 7:1 19:1 72:1 89:1 102:1 115:1 169:1 265:1 307:1 378:1 452:1 743:1 744:1 785:1 824:1 2229:1 2611:1 3482:1 4953:1 4954:1

1 	|BT| (S (NP (NN IR-5) (NN bear) (JJ novel) (NN point) (NN mutation) (NN HER2/neu)) (VP (VP (VBZ corresponds) (SBAR (S (NP (NN L726I) (JJ ATP-binding) (NN pocket)) (VP (VBP correlate) (NP (NN log) (NN decrease) (NN sensitivity) (NN gefitinib)))))) (, ,) (NP (NP (VBD increased) (NN heterodimerization) (NN EGFR) (NN HER3)) (, ,) (NP (JJ impaired) (NN down-regulation))))) |ET| |BS|63:G05.360.340.024.340.375.500.791.295.305 85:G02.111.087.225 259:D12.776.395.240.150.500 438:G05.365.590.675 455:B01.050.150.900.649.147.890 1064:Z01.252.245.500.350 1065:D01.268.556.401|ES| 2:1 19:1 34:1 47:1 187:1 257:1 295:1 607:1 891:1 901:1 1740:1 2003:1 2121:1 3310:1 3505:1 4281:1 4955:1 4956:1 4957:1 4958:1 4959:1 4960:1 4961:1

1 	|BT| (S (NP (NN Isochaihulactone)) (VP (VBD increased) (NP (NN EGR-1) (NN NAG-1) (NN mRNA) (NN protein) (NN expression)))) |ET| |BS|7:D12.776 111:D13.444.735.544 580:D12.776.260.158.500|ES| 4:1 19:1 47:1 115:1 325:1 1662:1 3874:1 4962:1

1 	|BT| (S (NP (NN Isochaihulactone) (NN treatment)) (VP (VBD increased) (NP (NP (NN luciferase)) (NP (NN activity) (NN NAG-1) (NN A549) (NN cell)) (NP (VBN transfected) (NN NAG-1) (NN promoter) (NN construct))))) |ET| |BS|41:A11 52:E02 1375:D08.811.682.517|ES| 19:1 47:1 83:1 94:1 364:1 399:1 479:1 546:1 1662:1 4962:1 4963:1 4964:1

1 	|BT| (S (NP (JJ Isochaihulactone-induced) (NN increase) (NN EGR-1) (NN NAG-1) (NN expression)) (VP (VBD reduced) (SBAR (S (NP (NP (NP (JJ mitogen-activated) (NN protein) (NN kinase) (NN kinase)) (CD 1/2) (NN inhibitor) (CD 2) ('' ')) (: -) (NP (NP (NN amino-3)) ('' ') (: -) (NP (NN methoxyflavone) (-LRB- -LRB-) (NN PD98059) (-RRB- -RRB-))) (, ,) (NP (NN effect))) (VP (VBD blocked) (NP (NP (NP (NP (NP (NN phosphatidylinositol) (JJ 3-kinase/protein) (NN kinase) (NN B) (NN pathway) (NN inhibitor) (CD 2)) (: -) (PRN (-LRB- -LRB-) (NP (NN 4-morpholinyl)) (-RRB- -RRB-))) (NN -8-phenyl-1)) (PRN (-LRB- -LRB-) (NP (NN 4H)) (-RRB- -RRB-))) (: -) (NP (NP (NN benzopyran-4-one) (NN hydrochloride)) (PRN (-LRB- -LRB-) (NP (NN LY294002)) (-RRB- -RRB-))))))))) |ET| |BS|122:C14.280.383 378:D08.811.913.696.620.682.700.755 580:D12.776.260.158.500 1376:D08.811.913.696.620.682.700.565.300 1377:D08.811.913.696.620.500.100|ES| 2:1 4:1 10:1 14:1 19:1 40:1 75:1 115:1 380:1 383:1 452:1 470:1 763:1 1662:1 2777:1 3295:1 3874:1 4588:1 4965:1 4966:1 4967:1 4968:1 4969:1 4970:1 4971:1 4972:1 4973:1 4974:1 4975:1 4976:1

1 	|BT| (S (NP (JJ Isochaihulactone-inducible) (NN gene)) (VP (VBD included) (S (NP (NP (JJ early) (NN growth) (NN response) (NN gene-1)) (PRN (-LRB- -LRB-) (NP (NN EGR-1)) (-RRB- -RRB-))) (NP (NP (JJ nonsteroidal) (JJ anti-inflammatory) (JJ drug-activated) (NN gene)) (PRN (-LRB- -LRB-) (NP (NN NAG-1)) (-RRB- -RRB-)))))) |ET| |BS|6:G05.360.340.024.340 45:G07.700.320.249 796:D27.505.696.663.850.014.040.500|ES| 9:1 10:1 14:1 19:1 102:1 494:1 1128:1 1528:1 1662:1 1859:1 2795:1 3046:1 3874:1 4977:1 4978:1

1 	|BT| (S (NP (PRP It)) (VP (VBD augmented) (SBAR (S (NP (NN caspase-3) (NN activity)) (VP (VBD downregulated) (NP (NP (NN expression) (NN Bcl-2)) (, ,) (NP (NN Bcl-xL)) (, ,) (NP (NN cIAP1) (NN cFLIP)))))))) |ET| |BS|54:G05.360.340.024.340.375.500.791.150 906:D08.811.277.656.262.500.126.350.300|ES| 2:1 19:1 115:1 158:1 399:1 426:1 1327:1 4807:1 4814:1 4979:1 4980:1 4981:1

1 	|BT| (NP (NP (NP (NN KLF4)) (NP (ADVP (RB therefore)) (NP (JJ potential) (NN mediator) (NN antitumor) (NN effect) (NN Notch) (NN inhibitor) (NN dibenzazepine))))) |ET| |BS||ES| 19:1 75:1 218:1 256:1 380:1 827:1 1892:1 2244:1 3018:1 3351:1

1 	|BT| (FRAG (NN Ku70) (: -) (: /) (: -) (FRAG (S (NP (NNS HCCs)) (VP (VBD showed) (SBAR (S (NP (JJ high) (JJ proliferative) (NN activity)) (VP (VBD increased) (S (NP (NN cyclin) (NN D1)) (VP (VBG proliferating) (NP (NN cell) (JJ nuclear) (NN antigen) (NN expression))))))))) (, ,) (NP (NP (NNP Aurora) (NNP A) (NN kinase) (NN activity)) (, ,) (VP (VP (VBD enhanced) (NP (NP (NN ataxia) (NN telangiectasia)) (NP (VBN mutated) (NN kinase) (NN ubiquitination)))) (, ,) (NP (NP (NN loss) (NN p53)) (PP (IN via) (NP (NP (JJ proteasomal) (NN degradation)) (, ,) (S (NP (NN feature)) (ADVP (RB closely)) (VP (VBP resemble) (NP (JJ human) (NN HCC))))))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 55:B01.050.150.900.649.801.400.112.400.400 104:C04.557.470.200.025.255 215:D12.644.360.262.150.100 469:D08.811.913.696 520:C10.228.140.252.190.530.060 768:D12.776.660.740 1281:D05.500.562.500 1293:G03.495 1378:D08.811.913.696.620.682.700.103.500 1379:G02.111.087.675.871.790.600.925|ES| 2:1 12:1 19:1 32:1 36:1 47:1 69:1 94:1 115:1 132:1 178:1 229:1 385:1 399:1 441:1 470:1 596:1 597:1 743:1 744:1 855:1 1030:1 1132:1 1250:1 1256:1 2865:1 4117:1 4556:1 4982:1 4983:1 4984:1 4985:1 4986:1 4987:1

1 	|BT| (S (NP (NNS Levels) (NN PGE2)) (VP (VBD correlated) (NP (NN YAP) (NN level) (JJ human) (JJ sporadic) (JJ colorectal) (NN tumor) (JJ colitis-associated) (NN tumor)))) |ET| |BS|8:C04 53:C06.405.205.265 55:B01.050.150.900.649.801.400.112.400.400 1031:C04.588.274.476.411.307 1118:D10.251.355.255.550.250.200|ES| 7:1 17:1 19:1 36:1 249:1 410:1 446:1 725:1 4988:1 4989:1 4990:1

1 	|BT| (FRAG (S (NP (NN LRAT) (NN deficiency)) (VP (VBD decreased) (SBAR (S (NP (JJ diethylnitrosamine-induced) (NN injury) (NN tumour) (NN load)) (VP (VBD increased) (NP (NN expression) (JJ retinoic) (NN acid) (JJ responsive) (NN gene) (NN Cyp26a1))))))) (, ,) (NP (NP (NN RARb) (NN p21)) (, ,) (VP (VBG suggesting) (S (NP (JJR lower) (NN tumour) (NN load) (JJ LRAT-deficient) (NN mouse) (NN result)) (VP (VBD increased) (NP (NN retinoid) (NN signalling) (JJ subsequent) (JJ p21-mediated) (NN inhibition) (NN proliferation))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 43:F01.145.544 87:C18.654.521 155:G05.355.310 554:D02.654.442.200 711:D02.455.326.271.665.202.495 770:D02.455.326.271.665.202.495.818.500 1380:E05.041.124.892|ES| 2:1 9:1 19:1 47:1 52:1 101:1 103:1 115:1 117:1 202:1 253:1 299:1 1009:1 1011:1 1135:1 1275:1 1319:1 2416:1 2437:1 2573:1 2704:1 2732:1 4140:1 4801:1 4991:1 4992:1 4993:1 4994:1 4995:1

1 	|BT| (S (NP (NN MBO-asGCS)) (VP (VBD suppressed) (NP (NP (NN expression) (NN MDR1) (NNS GCS)) (NP (VBN sensitized) (NN NCI/ADR-RES) (NN tumor) (NN doxorubicin))))) |ET| |BS|8:C04 120:I01.409.418.750.600.480.150 136:D02.455.426.559.847.562.050.200.175|ES| 7:1 19:1 115:1 307:1 453:1 598:1 599:1 4697:1 4761:1 4764:1

1 	|BT| (S (S (NP (NNP Mebendazole) (JJ single) (NN agent)) (VP (VBD decreased) (NP (NN COX2) (NN expression)))) (, ,) (NP (NP (NN blood) (NN vessel) (NN formation)) (, ,) (NP (NN VEGFR2) (NN phosphorylation)) (, ,)) (VP (VBD worked) (ADVP (RB synergistically)) (S (NP (NN sulindac)) (VP (VB reduce) (NP (NP (NN overexpression) (NN MYC)) (, ,) (NP (NN BCL2)) (, ,) (NP (JJ various) (JJ pro-inflammatory) (NN cytokine))))))) |ET| |BS|20:G03.495 30:Z01.058.290.190.800 31:D08.811.520.224.800 54:G05.360.340.024.340.375.500.791.150 251:D02.455.426.559.847.486.875 371:A07.231 445:I03.946 752:D12.644.276.374 805:F01.829.263.315.500.725 806:F01.829.263.315.500.725 972:G02.111.087.677 1185:D12.125.072.401.623 1381:D08.811.913.696.620.682.725.400.950.200 1382:D02.241.081.251.415|ES| 2:1 19:1 43:1 115:1 152:1 202:1 472:1 728:1 869:1 1096:1 1559:1 2361:1 2676:1 2846:1 3349:1 3426:1 3685:1 4118:1 4718:1 4996:1 4997:1 4998:1 4999:1

1 	|BT| (S (VP (ADVP (RB Mechanistically)) (, ,) (VP (VBD demonstrated) (SBAR (S (NP (NN EPLE)) (VP (VBD exerted) (NP (NN function) (VBG suppressing) (NN Wnt) (NN signaling) (NN pathway)))))) (, ,) (VP (VBN evidenced) (NP (NP (JJ EPLE-mediated) (NN downregulation) (NN Wnt) (NN target) (NN gene) (NN c-Myc)) (, ,) (NP (NN Axin2) (NN Survivin)))))) |ET| |BS|6:G05.360.340.024.340 85:G02.111.087.225 147:G02.149.115.800.925|ES| 2:1 9:1 19:1 33:1 160:1 195:1 308:1 383:1 595:1 824:1 877:1 1175:1 2102:1 2250:1 2489:1 3779:1 5000:1 5001:1 5002:1

1 	|BT| (S (NP (NN Meloxicam) (NN therapy)) (VP (VBD inhibited) (NP (NN cell) (NN proliferation)) (, ,) (VP (VBD induced) (NP (NP (NN cell) (NN apoptosis)) (, ,) (NP (NP (VBN reduced) (NN expression)) (VP (VBG proliferating) (NP (NN cell) (JJ nuclear) (NN antigen)))) (, ,))) (NP (NP (VBD increased) (NP (NN activation) (NN caspase-3))) (, ,) (NP (VBN upregulated) (NN Bax))))) |ET| |BS|8:C04 39:G04.299.139.160 41:A11 52:E02 122:C14.280.383 183:G04.299.233.750 342:D12.644.360.075.718.400 371:A07.231 768:D12.776.660.740 906:D08.811.277.656.262.500.126.350.300 1067:D12.644.276.624.120 1130:D12.644.276.390 1383:D27.505.696.377.077.077|ES| 2:1 5:1 7:1 19:1 47:1 75:1 89:1 94:1 102:1 115:1 125:1 130:1 185:1 225:1 299:1 365:1 412:1 452:1 1030:1 1251:1 1256:1 2213:1 2502:1 2865:1 3092:1 3733:1 4630:1 4807:1 4947:1 5003:1

1 	|BT| (NP (NP (NP (NNS METHODS)) (CC AND) (NP (NNS RESULTS)) (: :)) (S (NP (JJ Endogenous) (NN ROS) (NN production) (JJ CYP2E1-expressing) (NN HepG2) (NN cell)) (VP (VBD induced) (NP (NP (NP (NN mRNA) (NN protein) (NN expression) (NN KLF6)) (PRN (-LRB- -LRB-) (ADJP (JJ Full)) (-RRB- -RRB-))) (NN splice) (NN variant)) (S (VP (VBN compared) (NP (NN control) (NN cell))))))) |ET| |BS|7:D12.776 30:Z01.058.290.190.800 31:D08.811.520.224.800 41:A11 111:D13.444.735.544 168:E05.581 1015:A11.251.860.180.432 1218:D08.244.453.300|ES| 4:1 10:1 14:1 19:1 50:1 94:1 104:1 115:1 289:1 325:1 412:1 565:1 688:1 710:1 990:1 2356:1 2677:1 3481:1 4116:1 4683:1 4684:1 5004:1 5005:1

1 	|BT| (S (NP (NP (NNS Mice)) (VP (VBG receiving) (NP (NN NaTC)))) (VP (VBD manifested) (NP (NP (VBN increased) (JJ intestinal) (NN expression) (JJ FXR-regulated) (NN gene)) (, ,) (NP (NP (NNP Shp)) (, ,) (NP (NNP FGF15) (NNP IBABP)) (, ,) (NP (JJ concomitant) (NN decrease) (NN cyclin) (NN D1) (NN message)))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 47:A03.556.124 142:I01.880.604 155:G05.355.310 215:D12.644.360.262.150.100|ES| 2:1 9:1 19:1 47:1 109:1 115:1 295:1 548:1 583:1 743:1 744:1 1681:1 1928:1 4507:1 5006:1 5007:1 5008:1 5009:1 5010:1

1 	|BT| (S (NP (NN Microarray) (NN analysis) (NN liver) (NN sample)) (VP (VBD showed) (SBAR (S (NP (NN arsenic)) (VP (VBD induced) (NP (NP (JJ aberrant) (NN gene) (NN expression)) (PP (VBG including) (NP (NP (JJ steroid-related) (NN gene)) (, ,) (NP (NN cytokine)) (, ,) (NP (JJ apoptosis-related) (NN gene) (NN cell) (JJ cycle-related) (NN gene)))))))))) |ET| |BS|6:G05.360.340.024.340 39:G04.299.139.160 155:G05.355.310 242:A03.620 718:E05.588.570 752:D12.644.276.374 996:G05.360.340.024.340.220 1158:D01.268.513.249 1384:D04.808|ES| 2:1 9:1 19:1 94:1 115:1 132:1 412:1 561:1 661:1 835:1 836:1 1725:1 2676:1 3738:1 4106:1 4542:1 4571:1 5011:1

1 	|BT| (S (NP (NN MK-801)) (VP (VBN dephosphorylated) (S (NP (NN Thr24) (NN FOXO1)) (VP (VBD induced) (NP (JJ nuclear) (NN translocation)) (, ,) (ADVP (RB thus)) (VP (VP (VBG increasing) (NP (NN transcription) (NN TXNIP))) (, ,) (NP (NN tumor) (NN suppressor) (NN gene))))))) |ET| |BS|206:G05.360.340.024.340.375.249 209:G02.111.087.847 463:C23.550.210.870 1297:D02.455.426.559.847.181.384.380|ES| 2:1 7:1 9:1 19:1 412:1 487:1 700:1 715:1 1256:1 1334:1 1618:1 3264:1 4624:1 4625:1 4626:1 4627:1

1 	|BT| (S (S (NP (NP (NN MLN8237)) (, ,) (NP (JJ investigational) (JJ small-molecule) (JJ selective) (NN inhibitor) (NN AURKA)) (, ,)) (VP (VBD reduced) (S (NP (NP (JJ nuclear) (NN staining) (JJ nuclear) (NN factor-kappaB)) (PRN (-LRB- -LRB-) (NP (NN NF-kappaB)) (-RRB- -RRB-))) (VP (NN p65) (NP (JJ human) (JJ gastric) (NN cancer) (NN sample) (NN mouse) (JJ epithelial) (NN cell)))))) (, ,) (VP (VBD suppressed) (SBAR (S (NP (NP (NN NF-kappaB) (NN reporter) (NN activity)) (, ,) (NP (VBN reduced) (NN expression) (NN NF-kappaB) (NN target) (NN gene))) (VP (VBP regulate) (NP (NN inflammation) (NN cell) (NN survival))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 12:Z01.542.049 55:B01.050.150.900.649.801.400.112.400.400 75:A11.436 108:G04.299.316 155:G05.355.310 210:D12.776.260.600 225:E05.337 525:C23.550.470 1378:D08.811.913.696.620.682.700.103.500|ES| 2:1 9:1 10:1 14:1 18:1 19:1 36:1 52:1 86:1 94:1 115:1 127:1 160:1 274:1 288:1 307:1 380:1 399:1 452:1 714:1 835:1 858:1 1256:1 1605:1 1749:1 2702:1 3064:1 5012:1 5013:1 5014:1 5015:1 5016:1

1 	|BT| (S (NP (NP (NP (NN Modulation) (NN dasatinib)) (PRN (-LRB- -LRB-) (NP (NN c-Src) (NN inhibitor)) (-RRB- -RRB-))) (NN cytotoxicity) (NN STAT3) (NN knockdown)) (VP (VBN measured) (NP (NP (NNP MTT)) (, ,) (NP (NN cell) (NN cycle)) (, ,) (NP (NN apoptosis) (NN assay))))) |ET| |BS|39:G04.299.139.160 82:D12.644.360.024.342.300 106:E05.091 228:E05.978 353:G04.299.134 946:D27.888.569.213 1385:G05.360.340.024.340.375.500.791.570 1386:D02.886.675.184|ES| 2:1 10:1 14:1 19:1 89:1 94:1 251:1 310:1 380:1 464:1 601:1 789:1 2760:1 3317:1 5017:1 5018:1 5019:1

1 	|BT| (S (ADVP (RBR More) (RB importantly)) (, ,) (NP (NN ATRA)) (VP (VBD downregulated) (NP (NN expression) (NNP CSC) (NN marker) (NN CD44) (NN ALDH)) (SBAR (S (NP (ADJP (RB well) (JJ stemness)) (NN gene) (NN Klf4) (NN Sox2)) (VP (VBD induced) (NP (NN differentiation) (NNS tumorspheres))))))) |ET| |BS|6:G05.360.340.024.340 74:G04.299.151 158:D23.101 556:C11.768.175 770:D02.455.326.271.665.202.495.818.500 1387:D12.776.260.719.100|ES| 2:1 9:1 19:1 115:1 215:1 412:1 426:1 534:1 787:1 1581:1 2767:1 2768:1 3577:1 5020:1 5021:1 5022:1 5023:1 5024:1 5025:1

1 	|BT| (FRAG (ADVP (RB Moreover)) (, ,) (SBAR (IN although) (NP (NP (NP (NP (JJ sulindac-mediated) (NN induction) (NN p21)) (PRN (-LRB- -LRB-) (NP (NN cip/waf1)) (-RRB- -RRB-))) (ADJP (CD 113) (NN %)) (JJ wild-type) (NN HT-29)) (, ,) (S (NP (NN induction)) (VP (VBD alleviated) (NP (NP (NNP Csk) (NN shRNA) (NNS transfectants)) (PRN (-LRB- -LRB-) (NP (NP (ADJP (CD 65) (NN %)) (NN induction)) (: ;) (NP (NP (NN P)) (ADJP (JJR <) (NP (CD 0.01))))) (-RRB- -RRB-)))))))) |ET| |BS|251:D02.455.426.559.847.486.875 792:A11.251.210.190.475 1273:D13.150.650.700|ES| 2:1 8:1 10:1 14:1 19:1 217:1 311:1 312:1 315:1 369:1 622:1 736:1 1135:1 1592:1 2782:1 4230:1 4235:1 5026:1 5027:1 5028:1 5029:1 5030:1 5031:1

1 	|BT| (S (ADVP (RB Moreover)) (, ,) (S (NP (NN curcumin)) (VP (VBD suppressed) (NP (NP (NN NF-kappaB) (NN activity) (NN expression) (JJ NF-kappaB-regulated) (NN gene) (NN product)) (PRN (-LRB- -LRB-) (NP (NP (NN cyclin) (NN D1)) (, ,) (NP (NN c-myc)) (, ,) (NP (NN Bcl-2)) (, ,) (NP (NN Bcl-xL)) (, ,) (NP (JJ cellular) (NN inhibitor) (NN apoptosis) (NN protein-1)) (, ,) (NP (NN cyclooxygenase-2)) (, ,) (NP (NN matrix) (NN metalloproteinase-9)) (, ,) (NP (JJ vascular) (JJ endothelial) (NN growth) (NN factor))) (-RRB- -RRB-))))) (, ,) (NP (JJ many)) (VP (VBD induced) (SBAR (S (NP (NN radiation) (NN therapy)) (VP (VBP mediate) (NP (NN radioresistance))))))) |ET| |BS|7:D12.776 24:D08.811.600.720.750 41:A11 54:G05.360.340.024.340.375.500.791.150 142:I01.880.604 155:G05.355.310 210:D12.776.260.600 215:D12.644.360.262.150.100 281:E02.815 371:A07.231 586:D08.811.277.656.300.480.205.360 692:D02.455.326.146.485.222.222 1130:D12.644.276.390|ES| 2:1 9:1 10:1 14:1 19:1 61:1 89:1 102:1 115:1 130:1 158:1 185:1 307:1 380:1 399:1 412:1 455:1 622:1 675:1 714:1 743:1 744:1 1040:1 1251:1 1601:1 2157:1 2498:1 2500:1 2501:1 3074:1 3092:1 3491:1 4814:1 5032:1 5033:1

1 	|BT| (S (ADVP (RB Moreover)) (, ,) (VP (NP (NN DENA)) (VP (VBD decreased) (NP (NP (NN gene) (NN expression) (NN GSHPx)) (, ,) (NP (NN GST) (NN CAT)))) (VP (VBD caused) (NP (JJ severe) (JJ histopathological) (NN lesion) (NN liver) (NN tissue))))) |ET| |BS|98:A10 155:G05.355.310 242:A03.620 554:D02.654.442.200 1388:B01.050.150.900.649.147.354.250.125 1389:B01.050.150.900.649.147.354.250|ES| 2:1 9:1 19:1 115:1 202:1 272:1 622:1 836:1 1131:1 2506:1 3527:1 4413:1 5034:1 5035:1 5036:1 5037:1

1 	|BT| (S (VP (ADVP (RB Moreover)) (, ,) (NP (NN inhibition) (NN EIF5A) (JJ small) (S (VP (VBG interfering) (NP (NP (NP (NN RNA) (-LRB- -LRB-) (NN siRNA) (-RRB- -RRB-) (NN deoxyhypusine) (NN synthase)) (PRN (-LRB- -LRB-) (NP (NN DHPS)) (-RRB- -RRB-))) (NP (NN inhibitor) (NN GC7)))))) (, ,) (VP (VBZ inhibits) (NP (NN EIF5A2) (NN maturation))) (, ,) (VP (MD could) (ADVP (RB effectively)) (VP (VB decrease) (NP (NN cell) (NN motility)))))) |ET| |BS|43:F01.145.544 117:D13.150.650.700 122:C14.280.383|ES| 2:1 10:1 14:1 19:1 66:1 94:1 103:1 295:1 351:1 380:1 515:1 615:1 622:1 750:1 908:1 1177:1 1311:1 2977:1 3019:1 5038:1 5039:1 5040:1 5041:1 5042:1

1 	|BT| (S (ADVP (RB Moreover)) (, ,) (NP (NN MCC-555)) (VP (VBD increased) (NP (JJ transcriptional) (NN activity) (JJ human) (NN mouse) (NN MUC2) (NN promoter)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 209:G02.111.087.847 1390:I03|ES| 2:1 19:1 36:1 47:1 52:1 83:1 212:1 399:1 559:1 622:1 5043:1

1 	|BT| (FRAG (ADVP (RB Moreover)) (, ,) (NP (NP (NP (NN tumor) (NN necrosis) (NN factor) (NN alpha)) (PRN (-LRB- -LRB-) (NP (NN TNFalpha)) (-RRB- -RRB-))) (: -) (NP (NP (JJ 5-FU-induced) (NN apoptosis)) (VP (ADVP (RB greatly)) (VBD enhanced) (SBAR (S (NP (NN G17) (NN treatment) (NN Colo320wt) (NN cell)) (VP (VBD prevented) (SBAR (S (NP (NN IEX-1) (NN expression)) (VP (VBD repressed))))))))))) |ET| |BS|39:G04.299.139.160 41:A11 52:E02 560:D03.383.742.698.875.404 789:D12.644.276.374.500.800 790:D12.644.276.374.750|ES| 2:1 7:1 10:1 14:1 19:1 89:1 94:1 115:1 185:1 385:1 466:1 546:1 622:1 760:1 1836:1 1944:1 2691:1 3398:1 3984:1 4257:1 4685:1 4696:1 5044:1

1 	|BT| (NP (NP (JJ Negative) (NN regulation) (JJ oncogenic) (NN transcription) (NN factor) (NN FoxM1) (NNS thiazolidinediones) (NN mithramycin))) |ET| |BS|142:I01.880.604 166:D12.776.930 279:D27.888.569.100 862:D02.886.675.933 1303:D02.455.426.559.847.562.050.650|ES| 19:1 185:1 438:1 487:1 953:1 3118:1 4659:1 4791:1 5045:1

1 	|BT| (S (ADVP (RB Nevertheless)) (, ,) (NP (NN extent) (NN NAG-1) (NN induction)) (VP (MD could) (NP (VBN altered) (NN ERK) (NN inhibitor) (NN PD98059)))) |ET| |BS||ES| 2:1 19:1 380:1 693:1 736:1 908:1 1662:1 4486:1 4968:1 5046:1 5047:1

1 	|BT| (S (NP (NN Niclosamide)) (VP (VBD caused) (NP (NP (NN dose)) (: -) (NP (NP (NP (JJ time-dependent) (NN reduction) (NN beta-catenin) (JJ key) (NN component)) (PRN (-LRB- -LSB-) (PP (FW e.g.) (, ,) (NP (NP (NNS DVLs)) (, ,) (NP (NP (NN phospho-GSK3beta)) (PRN (-LRB- -LRB-) (NP (NN S9)) (-RRB- -RRB-))) (, ,) (NP (NN c-Myc) (NN Cyclin) (NN D1)))) (-RRB- -RSB-))) (JJ canonical) (NN Wnt/beta-catenin) (NN pathway))))) |ET| |BS|23:D12.776.091.249 105:G02.149.115.800.925 215:D12.644.360.262.150.100 322:G01.910 1391:D02.065.199.860.470|ES| 2:1 10:1 14:1 19:1 60:1 159:1 302:1 370:1 383:1 744:1 824:1 1021:1 1373:1 1378:1 1997:1 2506:1 3236:1 4742:1 5048:1 5049:1 5050:1 5051:1 5052:1 5053:1

1 	|BT| (NP (NP (JJ Nicotine-induced) (ADJP (NN survival) (NN signaling) (NN lung) (NN cancer) (NN cell) (JJ dependent)) (ADJP (NN p53) (NN status) (NN down-regulation) (NN curcumin) (JJ independent)))) |ET| |BS|2:G05.360.340.024.340.375.249.385 69:G02.111.087.800 85:G02.111.087.225 96:I03.784 108:G04.299.316 692:D02.455.326.146.485.222.222 1392:D03.132.760.570|ES| 12:1 18:1 19:1 94:1 195:1 257:1 274:1 321:1 328:1 416:1 883:1 2498:1 5054:1

1 	|BT| (S (DT No) (NP (NP (NP (NP (NN PPARgamma/retinoid) (NN X) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN RXR)) (-RRB- -RRB-))) (NP (NN consensus) (NN DNA) (NN binding) (NN site))) (VP (VBD detected) (NP (NP (NN FoxM1) (NN promoter)) (VP (VBG extending) (NP (NP (CD -10) (NN kb)) (NP (RB upstream) (, ,) (JJ knockdown) (NN PPARgamma) (NN impact) (NN TZD))))))) (VP (VBD mediated) (NP (NN downregulation) (NN FoxM1) (NN expression)))) |ET| |BS|13:D01.339.387 85:G02.111.087.225 198:D13.444.308 719:D12.776.826.239.588 1393:D12.776.826.701.500 1394:F01.829.316.068 1395:G02.111.570.120|ES| 2:1 10:1 14:1 19:1 83:1 115:1 186:1 437:1 464:1 595:1 666:1 929:1 1003:1 1007:1 1487:1 1996:1 2588:1 3119:1 3541:1 3660:1 4791:1 5055:1 5056:1 5057:1 5058:1 5059:1 5060:1

1 	|BT| (S (NP (NN NO-ASA)) (VP (VBD reduced) (NP (NP (NN expression) (NN cyclin) (NN D1)) (, ,) (NP (NP (JJ downstream) (NN target) (NN gene) (NN play) (JJ important) (NN role)) (NN colon) (NN carcinogenesis))))) |ET| |BS|6:G05.360.340.024.340 12:Z01.542.049 15:F01.829.316.616 33:C04.697.098 46:A03.556.124.526.356 79:I03.450.642.693 215:D12.644.360.262.150.100|ES| 2:1 9:1 19:1 31:1 113:1 115:1 160:1 207:1 238:1 452:1 560:1 743:1 744:1 902:1 3892:1

1 	|BT| (S (NP (JJ Novel) (NN oligoamine) (NN analogue)) (VP (VBP inhibit) (SBAR (S (NP (JJ lysine-specific) (NN demethylase) (CD 1)) (VP (VBP induce) (NP (NN reexpression)) (VP (ADVP (RB epigenetically)) (NP (VBN silenced) (NN gene)))))))) |ET| |BS|6:G05.360.340.024.340 122:C14.280.383 259:D12.776.395.240.150.500 1311:D12.125.068.555|ES| 9:1 19:1 98:1 243:1 1370:1 1380:1 2656:1 2658:1 5061:1 5062:1 5063:1 5064:1 5065:1

1 	|BT| (S (NP (NN Nrf2)) (VP (VBZ transactivates) (SBAR (S (NP (JJ wide) (NN variety)) (VP (VBP ARE) (PRN (-LRB- -LRB-) (NP (JJ anti-oxidant) (NN response) (NN element)) (-RRB- -RRB-)))))) (: -) (VP (VBN mediated) (NP (NN enzyme) (PP (VBG including) (NP (NN GSTP1-1)))))) |ET| |BS|730:D08.811 799:D12.776.260.615.249 1396:G02.111.570.080.689.675.700.040 1397:D08.811.913.225.500.500|ES| 10:1 14:1 19:1 494:1 561:1 952:1 2388:1 4048:1 4355:1 4522:1 5066:1 5067:1 5068:1 5069:1 5070:1

1 	|BT| (S (NP (JJ Oral) (NN administration) (NN gefitinib) (JJ able) (VBP prevent) (NP (NN outgrowth) (NN Bam1a) (NN tumor) (NN cell) (JJ palpable) (NN lesion))) (PRN (, ,) (S (VP (VB shrink) (NP (VBN established) (NN tumor)))) (, ,)) (VP (VB eliminate) (NP (NP (NN HER2) (NN HER3) (NN phosphorylation)) (, ,) (NP (NP (NN decrease) (NN MAPK) (NN Akt) (NN signaling)) (FW vivo))))) |ET| |BS|8:C04 30:Z01.058.290.190.800 31:D08.811.520.224.800 41:A11 63:G05.360.340.024.340.375.500.791.295.305 65:D08.811.913.696.620.682.725.400.009.400 69:G02.111.087.800 378:D08.811.913.696.620.682.700.755 385:F02.784.629.131 739:E02.319.267.100 972:G02.111.087.677|ES| 2:1 7:1 19:1 94:1 188:1 195:1 295:1 378:1 733:1 809:1 1131:1 1289:1 2575:1 2660:1 2832:1 3310:1 3426:1 4031:1 4961:1 5071:1 5072:1 5073:1 5074:1 5075:1

1 	|BT| (NP (NP (NP (NP (NNP Ornithine) (NN decarboxylase)) (PRN (-LRB- -LRB-) (NP (NN ODC)) (-RRB- -RRB-))) (, ,) (NP (JJ first) (NN enzyme) (NN polyamine) (NN synthesis)) (, ,) (NP (JJ transcriptional) (NN target) (NN c-myc) (NN modifier) (JJ APC-dependent) (NN tumorigenesis)))) |ET| |BS|3:C04.557.470.035.215.100 20:G03.495 32:C04.697.098.500 33:C04.697.098 209:G02.111.087.847 730:D08.811 1313:D02.092.782 1398:D08.811.520.224.125.425|ES| 2:1 10:1 14:1 19:1 78:1 160:1 455:1 559:1 816:1 2388:1 2697:1 3436:1 3819:1 4672:1 5076:1 5077:1 5078:1

1 	|BT| (S (NP (PRP$ Our) (NNS data)) (VP (VBD revealed) (NP (NP (NN HBx)) (ADJP (JJ survivin-dependently) (S (VP (VBN down-regulated) (S (VP (NN miR-520b) (S (VP (VBG interacting) (NP (NN Sp1) (NN cell)))))))))))) |ET| |BS|41:A11 142:I01.880.604 351:A17.360|ES| 19:1 94:1 275:1 658:1 793:1 1283:1 2014:1 4856:1 5079:1 5080:1 5081:1

1 	|BT| (S (NP (PRP$ Our) (NNS data)) (VP (VBP suggest) (SBAR (S (NP (NN TZD)) (VP (VBD mediated) (NP (NN suppression) (NN Sp1) (JJ responsible) (NN downregulation) (NN FoxM1) (NN gene) (NN expression))))))) |ET| |BS|85:G02.111.087.225 155:G05.355.310|ES| 9:1 19:1 115:1 437:1 595:1 658:1 793:1 796:1 2132:1 2453:1 3119:1 4791:1 4856:1

1 	|BT| (S (NP (PRP$ Our) (NNS data)) (VP (VBP support) (NP (NP (NN PGG) (JJ multitargeting) (NN agent) (NN chemoprevention) (NN therapy) (NN prostate) (NN cancer)) (VP (VBG activating) (NP (NP (NN p53) (NN tumor) (NN suppressor) (NN pathway)) (VP (VBG inhibiting) (NP (NN STAT3) (JJ oncogenic) (NN signaling)))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 52:E02 69:G02.111.087.800 82:D12.644.360.024.342.300 122:C14.280.383 133:D01.248.497.158.685.750.744.600 253:E02.319.162 279:D27.888.569.100 1399:D12.776.260.820|ES| 7:1 12:1 18:1 19:1 77:1 130:1 195:1 251:1 383:1 413:1 658:1 700:1 728:1 793:1 870:1 880:1 953:1 1364:1 1958:1 5082:1

1 	|BT| (S (NP (PRP$ Our) (NN finding)) (VP (VBP suggest) (SBAR (S (NP (NN NAG-1) (NN expression)) (VP (VBD up-regulated) (NP (NP (NN isochaihulactone) (JJ ERK-dependent) (NN pathway)) (VP (VBG involving) (NP (NN activation) (NN EGR-1))))))))) |ET| |BS|142:I01.880.604 150:Z01.542.248.960 580:D12.776.260.158.500 1400:G02.111.087.800.560|ES| 19:1 115:1 225:1 383:1 658:1 796:1 927:1 1301:1 1662:1 3874:1 4055:1 4889:1 5083:1

1 	|BT| (S (S (NP (PRP$ Our) (NN result)) (VP (VBD demonstrated) (SBAR (S (NP (NP (NN soy) (NN peptide)) (PRN (-LRB- -LRB-) (NP (CD 1)) (-RRB- -RRB-))) (VP (ADVP (RB dramatically)) (VBZ inhibits) (NP (NN expression) (NN HSP90))))) (, ,) (S (ADVP (RB thereby)) (VP (VBG suppressing) (NP (NN signaling) (NN pathway) (VBG leading) (NN NF-gammaB) (NN activation)))))) (: ;) (S (LST (-LRB- -LRB-) (LS 2) (-RRB- -RRB-)) (VP (VBZ induces) (NP (NP (NN expression) (NN p21)) (, ,) (NP (NP (NN p53)) (, ,) (NP (NN caspase-3) (NN protein))) (: ;) (S (LST (-LRB- -LRB-) (LS 3) (-RRB- -RRB-)) (VP (VBZ inhibits) (NP (NN expression) (NN VEGF)))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 7:D12.776 69:G02.111.087.800 86:D01.268.556.435 122:C14.280.383 126:G02.111.087.800 906:D08.811.277.656.262.500.126.350.300 1001:B01.650.940.800.575.100.401.750 1113:D12.776.580.216.380 1401:D12.644|ES| 2:1 4:1 10:1 12:1 14:1 19:1 98:1 101:1 115:1 148:1 195:1 214:1 217:1 225:1 383:1 615:1 639:1 645:1 658:1 862:1 1135:1 1175:1 2066:1 2250:1 4636:1 4807:1 4896:1 5084:1 5085:1 5086:1

1 	|BT| (NP (NP (PRP$ Our) (VBP result) (VBP indicate) (NN EGCG) (S (VP (VBZ attenuates) (S (NP (NN cell) (NN proliferation) (NN OSCC) (NN cell)) (VP (VBG upregulating) (NP (NN BTG2) (NN expression)) (PP (IN via) (NP (NN p38) (NN ERK) (NN pathway))))))))) |ET| |BS|38:Z01.058.290.120.180 40:Z01.542.248.700 41:A11 183:G04.299.233.750 1400:G02.111.087.800.560|ES| 19:1 94:1 101:1 115:1 299:1 383:1 596:1 658:1 1479:1 1666:1 2423:1 3140:1 4885:1 4886:1 5047:1 5087:1

1 	|BT| (S (NP (PRP$ Our) (NN result)) (VP (VBD showed) (SBAR (S (NP (NNP Protandim)) (VP (VBD suppressed) (NP (JJ mitochondrial) (NN translocation) (NN p53) (JJ mitochondrial) (JJ outer) (NN membrane) (NN protein) (NN Bax))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 342:D12.644.360.075.718.400 463:C23.550.210.870 565:A11.284.430.214.190.875.564 567:G05.360.340.024.340.365 1402:A11.284.149.450.349|ES| 4:1 12:1 19:1 101:1 132:1 307:1 658:1 1618:1 2004:1 3622:1 4630:1 5088:1 5089:1

1 	|BT| (NP (NN Overexpression) (S (NP (NP (NN c-Jun) (JJ N-terminal) (NN kinase) (CD 1)) (PRN (-LRB- -LRB-) (NP (NN JNK1)) (-RRB- -RRB-))) (VP (VBD resulted) (NP (NN miR-122) (NN down-regulation) (NN induction) (NN PTP1B))))) |ET| |BS|85:G02.111.087.225 469:D08.811.913.696|ES| 10:1 14:1 19:1 98:1 257:1 470:1 594:1 668:1 736:1 1686:1 1789:1 2357:1 5090:1 5091:1

1 	|BT| (S (S (NP (NN Overexpression) (NN NF-kappaB) (NN superrepressor)) (VP (VBD increased) (NP (NN PTEN) (NN expression) (NN JNK) (NN activity)))) (, ,) (IN whereas) (S (NP (NN overexpression) (NN p65) (NN NF-kappaB) (NN subunit)) (VP (VBD reduced) (NP (JJ basal) (JJ NaBT-mediated) (NN JNK) (NN activation) (NN PTEN) (NN expression))))) |ET| |BS|210:D12.776.260.600 583:D12.776.813|ES| 2:1 19:1 47:1 115:1 152:1 225:1 372:1 399:1 452:1 668:1 714:1 1936:1 2110:1 4184:1 4276:1 5016:1 5092:1 5093:1

1 	|BT| (S (NP (NN p66) (NN overexpression)) (ADVP (RB also)) (VP (VBD prevented) (NP (NP (NN activation) (NN luciferase) (NN reporter) (NN gene)) (VP (VBN controlled) (NP (NN SOD2) (NN promoter)))) (, ,) (S (VP (VBG indicating) (S (NP (NN p66) (NN repression) (NN MnSOD)) (VP (VBZ operates) (NP (JJ transcriptional) (NN level)))))))) |ET| |BS|208:F01.393.821 209:G02.111.087.847 264:G05.355.315.800 1375:D08.811.682.517 1403:D08.811.682.881|ES| 2:1 5:1 9:1 19:1 83:1 152:1 225:1 249:1 288:1 559:1 706:1 1944:1 2236:1 4601:1 4604:1 4963:1 5094:1 5095:1 5096:1

1 	|BT| (S (NP (NN Penta-1,2,3,4,6-O-galloyl-beta-D-glucose)) (VP (VP (VBZ induces) (SBAR (S (NP (NN p53)) (VP (VBZ inhibits) (NP (NN STAT3) (NN prostate) (NN cancer) (NN cell) (NN vitro)))))) (VP (VBZ suppresses) (NP (NN prostate) (NN xenograft) (NN tumor) (NN growth)) (FW vivo)))) |ET| |BS|2:G05.360.340.024.340.375.249.385 41:A11 45:G07.700.320.249 82:D12.644.360.024.342.300 91:D09.546.359.448 92:E04.936.764 93:A01.941.875 122:C14.280.383 202:C04.588.945.440.770|ES| 7:1 12:1 18:1 19:1 77:1 94:1 102:1 214:1 216:1 251:1 265:1 378:1 615:1 685:1 686:1

1 	|BT| (S (NP (NN Penta-O-galloyl-beta-D-glucose)) (VP (VBZ induces) (NP (NN G1) (NN arrest) (NN DNA) (JJ replicative) (NN S-phase) (NN arrest)) (NP (NP (ADJP (RB independently) (JJ cyclin-dependent)) (NN kinase) (NN inhibitor) (NN 1A)) (, ,) (NP (JJ cyclin-dependent) (NN kinase) (NN inhibitor) (NN 1B) (NN P53) (JJ human) (NN breast) (NN cancer) (NN cell)) (NP (RB orally) (JJ active) (JJ triple) (JJ negative) (NN xenograft) (NN growth))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 41:A11 45:G07.700.320.249 55:B01.050.150.900.649.801.400.112.400.400 91:D09.546.359.448 92:E04.936.764 93:A01.941.875 122:C14.280.383 198:D13.444.308 338:D12.644.360.225.600 1299:D12.644.360.225.500 1404:G02.111.087.222.880|ES| 2:1 18:1 19:1 23:1 36:1 94:1 102:1 197:1 214:1 265:1 380:1 449:1 470:1 602:1 666:1 670:1 1503:1 1916:1 2052:1 2149:1 4226:1 4546:1 5097:1 5098:1 5099:1 5100:1

1 	|BT| (S (NP (NN POX)) (ADVP (RB markedly)) (VP (VBD elevated) (SBAR (S (NP (JJ p53-induced) (NN apoptosis)) (VP (VBZ generates) (NP (JJ proline-dependent) (NP (NP (JJ reactive) (NN oxygen) (NN specie)) (PRN (-LRB- -LRB-) (NP (NN ROS)) (-RRB- -RRB-))))))) (, ,) (NP (NP (ADVP (RB specifically)) (NP (NN superoxide) (NN radical))) (, ,) (NP (VBP induce) (NN apoptosis) (JJ mitochondrial) (NN death) (NN receptor) (NN pathway))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 30:Z01.058.290.190.800 31:D08.811.520.224.800 39:G04.299.139.160 135:C23.550.260 565:A11.284.430.214.190.875.564 567:G05.360.340.024.340.365 636:D01.339.431 1185:D12.125.072.401.623 1405:D01.248.497.158.685.750.850|ES| 2:1 10:1 14:1 19:1 89:1 146:1 186:1 243:1 383:1 411:1 480:1 756:1 1279:1 2004:1 2353:1 2354:1 2355:1 2356:1 2396:1 5101:1 5102:1 5103:1 5104:1

1 	|BT| (S (NP (VBN Presented) (NNS data)) (VP (VP (VBP reveal) (S (NP (NN pterostilbene)) (ADJP (JJ novel)))) (, ,) (NP (NP (ADJP (ADJP (JJ effective)) (, ,) (ADJP (JJ anti-metastatic))) (NN agent) (NN function)) (VP (VBG downregulating) (NP (NN MMP-9) (NN gene) (NN expression)))))) |ET| |BS|155:G05.355.310 259:D12.776.395.240.150.500 586:D08.811.277.656.300.480.205.360|ES| 2:1 9:1 19:1 33:1 115:1 728:1 793:1 891:1 1639:1 1670:1 2065:1 2158:1 2428:1 5105:1 5106:1

1 	|BT| (S (S (NP (NN Pretreatment) (NN p38) (NN kinase) (NN inhibitor)) (VP (VBD blocked) (NP (JJ VES-induced) (NN increase) (NN NAG-1) (NN protein) (NN mRNA) (NN level)))) (, ,) (IN whereas) (NP (NP (NN inhibition) (NN protein) (NN kinase) (NN C)) (, ,) (NP (NN Akt)) (, ,) (FRAG (NN c-Jun) (NNP NH) (LST (-LRB- -LRB-) (LS 2) (-RRB- -RRB-)) (: -) (NP (NP (JJ terminal) (NN kinase)) (, ,) (NP (NP (NN MEK) (NN activity) (NN effect)) (JJ VES-induced) (NN NAG-1) (NN level)))))) |ET| |BS|7:D12.776 12:Z01.542.049 13:D01.339.387 43:F01.145.544 111:D13.444.735.544 122:C14.280.383 233:D08.811.913.696.620.682.700.565 234:D08.811.913.696.620.682.700.565 378:D08.811.913.696.620.682.700.755 469:D08.811.913.696 470:C02.782.160.927 992:D08.811.913.696.620.682.700.725 1406:D02.455.526.728.650.529|ES| 2:1 4:1 10:1 14:1 19:1 40:1 75:1 103:1 148:1 249:1 325:1 372:1 380:1 399:1 470:1 1289:1 1661:1 1662:1 1666:1 1686:1 1955:1 2777:1 5107:1 5108:1 5109:1 5110:1

1 	|BT| (S (NP (NP (NN Protein) (NN analysis)) (VP (VBN treated) (NP (NN tumor) (NN biopsy)))) (VP (VBD revealed) (NP (NP (NP (JJ elevated) (NN amount) (NN cell) (NN cycle) (NN regulator)) (NP (NN p21) (NN proapoptosis) (NN factor))) (, ,) (NP (NP (NN caspase) (CD 3)) (CD 7) (VBN cleaved) (NN poly) (-LRB- -LSB-) (NN ADP-ribose) (-RRB- -RSB-) (NN polymerase)) (, ,) (VP (VBN coupled) (VP (VBN decreased) (NP (NP (NN level) (JJ antiapoptotic) (NN factor) (NN Bcl-2) (NN Bcl-X)) (PRN (-LRB- -LRB-) (NP (NN L)) (-RRB- -RRB-)))))))) |ET| |BS|52:E02 54:G05.360.340.024.340.375.500.791.150 353:G04.299.134 418:D12.644.360.075.718.937 559:E01.370.225.500.384.100 906:D08.811.277.656.262.500.126.350.300 1248:D08.811.913.400.725.115.690 1407:D12.776.624|ES| 2:1 7:1 10:1 14:1 19:1 94:1 158:1 185:1 202:1 235:1 249:1 275:1 394:1 601:1 661:1 709:1 756:1 862:1 988:1 1099:1 1135:1 1373:1 1378:1 1436:1 1984:1 2911:1 4796:1 4809:1 4810:1 4811:1 5111:1 5112:1 5113:1 5114:1

1 	|BT| (S (NP (NN Rapamycin)) (VP (VBZ inhibits) (SBAR (S (NP (JJ multiple) (NN stage) (NN c-Neu/ErbB2)) (VP (VBD induced) (NP (NP (NN tumor) (NN progression) (JJ transgenic) (NN mouse) (NN model)) (NP (JJ HER2-positive) (NN breast) (NN cancer)))))))) |ET| |BS|8:C04 16:C23.550.291.656 63:G05.360.340.024.340.375.500.791.295.305 65:D08.811.913.696.620.682.725.400.009.400 99:B01.050.050.136.500 122:C14.280.383 827:D02.540.505.760 1002:C04.588.180|ES| 7:1 18:1 19:1 23:1 48:1 52:1 72:1 285:1 412:1 615:1 649:1 1129:1 2225:1 5115:1 5116:1

1 	|BT| (S (NP (NP (NNS Rats)) (VP (VBN fed) (NP (JJ high-dose) (NN CP-31398) (NN combination) (JJ low-dose) (NN CP-31398) (NN celecoxib)))) (VP (VBD showed) (NP (NP (NP (NP (NP (JJ considerable) (NN enhancement) (NN p53) (NN p21)) (PRN (-LRB- -LRB-) (NP (NN WAF1/CIP)) (-RRB- -RRB-))) (NN expression)) (, ,) (NP (NN apoptosis)) (, ,)) (VP (VBN reduced) (NP (NN tumor) (NN cell) (NN proliferation) (JJ colonic) (NN tumor)))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 8:C04 39:G04.299.139.160 51:C04.588.274.476.411.307.180 183:G04.299.233.750 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 663:C16.320.565.398.500.330.500 684:D02.065.884.247|ES| 2:1 7:1 10:1 12:1 14:1 19:1 89:1 94:1 115:1 132:1 299:1 452:1 530:1 677:1 1135:1 2278:1 2426:1 2807:1 3047:1 3049:1 3664:1 5117:1 5118:1 5119:1

1 	|BT| (NP (NP (RB Regardless) (NN p53) (NN status)) (, ,) (NP (NN celecoxib)) (VP (VBD caused) (NP (NP (JJ significant) (NN difference) (NN apoptosis) (NN level) (NN U87MG)) (, ,) (NP (NN U87MG-PFT)) (, ,) (NP (NN U87MG-E6) (NN U373MG) (NN cell))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 13:D01.339.387 39:G04.299.139.160 41:A11 684:D02.065.884.247|ES| 2:1 12:1 19:1 89:1 94:1 135:1 249:1 416:1 1674:1 2506:1 2807:1 4619:1 4620:1 4621:1 4623:1 5120:1

1 	|BT| (NP (NP (NP (NN Regulation) (NN PTEN) (NN expression) (JJ intestinal) (JJ epithelial) (NN cell) (NN c-Jun) (JJ NH2-terminal) (NN kinase) (NN activation)) (NP (JJ nuclear) (NN factor-kappaB) (NN inhibition)))) |ET| |BS|43:F01.145.544 47:A03.556.124 75:A11.436 142:I01.880.604 210:D12.776.260.600 771:D08.811.913.696.620.682.700.567.374|ES| 19:1 94:1 103:1 109:1 115:1 127:1 225:1 470:1 699:1 1256:1 1686:1 1936:1 2702:1 2708:1

1 	|BT| (NP (NP (NP (NN Relationship) (NN CYP1A) (NN induction) (NN indole-3-carbinol) (NN flutamide) (NN liver)) (JJ tumor-promoting) (JJ potential) (NN rat))) |ET| |BS|245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 515:C04.588.274.623 1172:D02.065.199.420|ES| 19:1 736:1 827:1 836:1 849:1 3647:1 3776:1 4057:1 5121:1 5122:1

1 	|BT| (S (ADVP (RB Remarkably)) (, ,) (NP (NP (NN F-box) (NN protein) (NN FBW7)) (, ,) (NP (NN E3-ubiquitin) (NN ligase)) (, ,)) (VP (VBN controlled) (NP (NP (NN stability) (NN arm) (NN c-MYC/MXD1) (JJ push-pull) (NN network)) (, ,) (NP (NN FBW7) (NN ablation)))) (S (VP (VBD attenuated) (NP (CD 1,25) (NN D) (NN regulation) (NN c-MYC) (NN MXD1) (NN turnover))))) |ET| |BS|142:I01.880.604 588:I01.880.853.500.600 665:N04.452.677.680 1408:C04.557.450.590.550.660.665 1409:D08.811.464.938.750 1410:A01.378.800.075|ES| 2:1 4:1 19:1 91:1 438:1 625:1 808:1 2154:1 2424:1 4529:1 4533:1 4950:1 5094:1 5123:1 5124:1 5125:1 5126:1 5127:1 5128:1 5129:1 5130:1

1 	|BT| (NP (NP (NN Repression) (NN MUC2) (NN gene) (NN expression) (NN butyrate)) (, ,) (NP (JJ physiological) (NN regulator) (JJ intestinal) (NN cell) (NN maturation))) |ET| |BS|47:A03.556.124 155:G05.355.310 208:F01.393.821 230:G04 1307:D02.241.081.114.750 1309:D02.241.081.114|ES| 2:1 9:1 19:1 94:1 109:1 115:1 212:1 235:1 3758:1 3762:1 5042:1 5131:1

1 	|BT| (S (NP (NNS RESULTS) (: :)) (S (NP (NP (NN Depletion) (NN c-Src) (JJ small) (VBG interfering) (NN RNA)) (VP (VBD sustained) (NP (NN inhibition) (NN dasatinib)))) (VP (VBD increased) (NP (NN pSTAT3)))) (, ,) (VP (MD could) (VP (VBD blocked) (NP (NN inhibition) (NN JAK))))) |ET| |BS|43:F01.145.544 117:D13.150.650.700 122:C14.280.383 1386:D02.886.675.184|ES| 2:1 19:1 47:1 103:1 104:1 515:1 710:1 750:1 908:1 1847:1 2777:1 3019:1 5017:1 5018:1 5132:1 5133:1 5134:1

1 	|BT| (NP (NP (NNS RESULTS) (: :)) (S (NP (NN MDR1) (NNS GCS)) (ADVP (RB coincidently)) (VP (VBN overexpressed) (NP (NP (JJ drug-resistant) (NN breast)) (, ,) (NP (NN ovary)) (, ,) (NP (JJ cervical) (NN colon) (NN cancer) (NN cell))))) (FRAG (: ;) (NP (NP (NN silencing) (NNS GCS)) (VP (VBG using) (NP (NP (NP (JJ novel) (NN mixed-backbone) (NN oligonucleotide)) (PRN (-LRB- -LRB-) (NP (NN MBO-asGCS)) (-RRB- -RRB-))) (VP (VBN sensitized) (NP (CD four) (JJ drug-resistant) (NN cell) (NN line) (NN doxorubicin)))))))) |ET| |BS|10:A01.236 41:A11 67:D26 94:A11.251.210 136:D02.455.426.559.847.562.050.200.175 259:D12.776.395.240.150.500 575:V02.050 1369:A05.360.319.114.630 1411:D13.695.578.424 1412:A02.835.232.834 1413:A01.598|ES| 2:1 10:1 14:1 18:1 19:1 23:1 25:1 94:1 100:1 104:1 113:1 217:1 264:1 350:1 453:1 598:1 599:1 710:1 891:1 3247:1 4188:1 4697:1 4761:1 5135:1 5136:1 5137:1 5138:1 5139:1

1 	|BT| (S (S (NP (NN Resveratrol)) (VP (VBD induced) (NP (NP (NN cell) (NN cycle) (NN arrest)) (VP (VBG up-regulating) (NP (NN expression) (NN p21/CIP1)))))) (, ,) (S (NP (NN p27/KIP1)) (VP (VBG inhibiting) (NP (NN expression) (NN cyclin) (NN D1))))) |ET| |BS|122:C14.280.383 150:Z01.542.248.960 215:D12.644.360.262.150.100 338:D12.644.360.225.600 773:G04.299.134.109|ES| 2:1 19:1 94:1 115:1 412:1 601:1 602:1 743:1 744:1 880:1 1876:1 2946:1 5140:1 5141:1

1 	|BT| (S (NP (NNP Resveratrol)) (VP (VBZ prevents) (S (NP (NN tumorigenesis) (NN mouse) (NN model)) (VP (NNP Kras) (VP (VBD activated) (S (NP (JJ sporadic) (JJ colorectal) (NN cancer)) (VP (VBG suppressing) (NP (JJ oncogenic) (NN Kras) (NN expression))))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 11:B01.050.150.900.649.865.635.505.500 32:C04.697.098.500 33:C04.697.098 279:D27.888.569.100 388:G05.360.340.024.340.375.500.791.550|ES| 17:1 18:1 19:1 52:1 72:1 78:1 115:1 163:1 725:1 953:1 2250:1 2718:1 2946:1 5142:1

1 	|BT| (S (NP (NN Retinol) (NN treatment)) (VP (VP (VBD decreased) (NP (NN transcription) (NN TOPFlash) (NN reporter) (NN construct) (NN mRNA) (NN level) (JJ endogenous) (NN beta-catenin) (NN target) (NN gene))) (, ,) (NP (NN cyclin) (NN D1) (NN c-myc)))) |ET| |BS|6:G05.360.340.024.340 23:D12.776.091.249 52:E02 111:D13.444.735.544 209:G02.111.087.847 215:D12.644.360.262.150.100 1414:D02.455.326.271.665.202.495.818 1415:D02.455.326.271.665.202.495.818|ES| 2:1 9:1 19:1 60:1 160:1 202:1 249:1 288:1 325:1 455:1 487:1 546:1 743:1 744:1 3870:1 4964:1 5143:1 5144:1

1 	|BT| (NP (NP (NP (NN Role)) (NP (VBN phosphorylated) (NN histone) (NN H3) (NN serine) (CD 10) (JJ DEN-induced) (NN deregulation) (NN Pol) (CD III) (NN gene) (NN cell) (NN proliferation) (NN transformation)))) |ET| |BS|15:F01.829.316.616 183:G04.299.233.750 614:G05.360.340.024.340.364.875.667 926:D12.125.154.800 1416:D12.776.660.470|ES| 9:1 19:1 94:1 299:1 402:1 503:1 1384:1 1519:1 2187:1 2280:1 2281:1 2735:1 4930:1 5145:1 5146:1

1 	|BT| (S (NP (NNS RWPs)) (VP (VBD reduced) (NP (SBAR (S (NP (NP (NN expression) (NN VEGF)) (, ,) (NP (NP (NP (NN matrix) (NN metalloproteinase)) (PRN (-LRB- -LRB-) (NP (NN MMP)) (-RRB- -RRB-))) (CD -2) (, ,) (NN MMP-9) (, ,) (NN cyclooxygenase-2))) (VP (VBD increased) (NP (NN expression) (NN tumor) (NN suppressor) (NN gene) (NN p16) (-LRB- -LRB-) (NN INK4A) (-RRB- -RRB-))))) (, ,) (NP (NN p53) (, ,) (NN p73) (NN tumor) (NN cell))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 8:C04 24:D08.811.600.720.750 41:A11 155:G05.355.310 203:G05.360.340.024.340.375.249.375 206:G05.360.340.024.340.375.249 586:D08.811.277.656.300.480.205.360 1417:D08.811.277.656.300.480.205.352|ES| 2:1 7:1 9:1 10:1 12:1 14:1 19:1 47:1 61:1 94:1 115:1 452:1 700:1 1313:1 2066:1 2158:1 2892:1 3182:1 3491:1 5147:1 5148:1 5149:1 5150:1

1 	|BT| (S (S (NP (NN SAHA)) (VP (VBD decreased) (NP (NN cyclin) (NN B1) (NN expression)))) (: ;) (S (NP (NN cyclin)) (ADVP (RB normally)) (VP (VBZ promotes) (NP (NN progression) (NN G2) (NN cell) (NN cycle))))) |ET| |BS|16:C23.550.291.656 353:G04.299.134 768:D12.776.660.740 979:D12.644.360.262.120.100 1280:D12.644.360.262|ES| 19:1 48:1 94:1 115:1 202:1 217:1 298:1 601:1 743:1 3455:1 4915:1 5151:1 5152:1

1 	|BT| (S (NP (NN Salinomycin)) (VP (VBD induced) (NP (NN degradation) (NN Skp2)) (ADVP (RB thus)) (VP (VBN accumulated) (NP (NN p27Kip1))))) |ET| |BS|338:D12.644.360.225.600 507:D12.776.157.743 1293:G03.495|ES| 19:1 412:1 597:1 1334:1 1785:1 4616:1 5153:1 5154:1

